Variables SVR no.(%) p univariate Adjusted OR(95% CI) P multivariate
Age (years) †        
< 41 34 (44)      
≥ 41 41 (47) 0.7 - -
Gender        
Male 55 (45)      
Female 20 (48) 0.7 - -
Body mass index†        
≤ 23 28 (48) 0.3    
> 23 25 (40)   - -
Baseline ALT†        
≤ 81 40 (43)      
> 81 35 (49) 0.4 - -
Injecting drug user        
Yes 60 (44)      
No 15 (52) 0.4 - -
CDC clinical category        
A-B 59 (50) 0.08 1.7 (0.7-3.9) 0.1
C 16 (35)      
Liver fibrosis        
≤ 2 29 (41)      
≥ 3 19 (41) 0.9 - -
Cirrhosis        
Yes 11 (44) 0.7 - -
No 37 (41)      
HCV genotype        
1-4 34 (33)      
2-3 41 (67) <0.001 5.4 (2.5-11.3) <0.001
Baseline HCV-RNA load (IU/mL)        
<600000 35 (54) 0.06 1.6 (0.7-3.4) 0.1
≥600000 39 (39)      
Daily dose of RBV (mg/kg) †        
< 14.8 32 (40)      
≥ 14.8 39 (48) 0.3 - -
Type of peg-IFN        
Alfa-2a 56 (43)      
Alfa-2b 19 (54) 0.2 - -
Initiation of peg-IFN treatment        
2001-2004 23 (45)      
2005-2008 52 (46) 0.9 - -
Exposure to HCV therapy        
< 80% 4 (23)      
≥ 80% 71 (48) 0.05 4.8 (1.3-17.8) 0.01
Baseline undetectable plasma HIV-RNA        
Yes 69 (48)      
No 6 (30) 0.1 - -
Baseline CD4 cell count/mm3†        
< 459 35 (42)      
≥ 459 40 (49) 0.4 - -
Baseline CD4 cell count/mm3        
≥ 200 71 (45)      
< 200 4 (50) 0.8 - -
Baseline LDL-cholesterol (mg/L)        
≥ 100 26 (54)      
< 100 29 (40) 0.1 - -
Third drug in ART combination        
NVP 40 (56) 0.015 2.5 (1.2-5.0) 0.01
LPV/r 35 (37)      
NRTI backbone during HCV therapy        
TDF plus 3TC 44 (42)      
TDF plus FTC 31 (51) 0.3 - -
†Categorized by median. ALT: alanine aminotransferase. RBV: ribavirin. peg-IFN: pegylated interferon. LDL: low-density lipoprotein. ART: antiretroviral therapy. NVP: nevirapine. LPV/r: lopinavir/ritonavir. NRTIs: nucleos (t) ide retrotranscriptase inhibitors. TDF: tenofovir. 3TC: lamivudine. FTC: emtricitabine.
Table 3: Sustained virologic response (SVR) according to different variables in the entire cohort.